Income Statement Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.430 USD | +0.13% |
|
-2.24% | -15.76% |
| 12:05am | Vanda Pharmaceuticals Inc., Q4 2025 Earnings Call, Feb 11, 2026 | |
| 02-11 | Vanda Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2026 | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 248M | 269M | 254M | 193M | 199M | |||||
Total Revenues | 248M | 269M | 254M | 193M | 199M | |||||
Cost of Goods Sold, Total | 23.36M | 25.63M | 24.28M | 14.8M | 11.31M | |||||
Gross Profit | 225M | 243M | 230M | 178M | 187M | |||||
Selling General & Admin Expenses, Total | 141M | 124M | 136M | 113M | 146M | |||||
R&D Expenses | 55.58M | 75.36M | 85.77M | 76.82M | 74.43M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 1.48M | 1.48M | 1.52M | 2.09M | 7.27M | |||||
Other Operating Expenses, Total | 198M | 201M | 224M | 192M | 228M | |||||
Operating Income | 27.24M | 42.16M | 6.33M | -13.95M | -40.66M | |||||
Interest And Investment Income | 4.42M | 199K | 4.97M | - | - | |||||
Net Interest Expenses | 4.42M | 199K | 4.97M | - | - | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | - | - | - | 11.49M | 10.74M | |||||
EBT, Excl. Unusual Items | 31.66M | 42.36M | 11.3M | -2.46M | -29.92M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | 8.8M | 6.99M | |||||
EBT, Incl. Unusual Items | 31.66M | 42.36M | 11.3M | 6.34M | -22.92M | |||||
Income Tax Expense | 8.32M | 9.21M | 5.02M | 3.83M | -4.02M | |||||
Earnings From Continuing Operations | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | |||||
Net Income to Company | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | |||||
Net Income - (IS) | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | |||||
Net Income to Common Incl Extra Items | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | |||||
Net Income to Common Excl. Extra Items | 23.34M | 33.15M | 6.28M | 2.51M | -18.9M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.43 | 0.6 | 0.11 | 0.04 | -0.33 | |||||
Basic EPS - Continuing Operations | 0.43 | 0.6 | 0.11 | 0.04 | -0.33 | |||||
Basic Weighted Average Shares Outstanding | 54.43M | 55.55M | 56.46M | 57.38M | 58.15M | |||||
Net EPS - Diluted | 0.42 | 0.58 | 0.11 | 0.04 | -0.33 | |||||
Diluted EPS - Continuing Operations | 0.42 | 0.58 | 0.11 | 0.04 | -0.33 | |||||
Diluted Weighted Average Shares Outstanding | 55.19M | 56.92M | 56.98M | 57.56M | 58.15M | |||||
Normalized Basic EPS | 0.36 | 0.48 | 0.13 | -0.03 | -0.32 | |||||
Normalized Diluted EPS | 0.36 | 0.47 | 0.12 | -0.03 | -0.32 | |||||
Supplemental Items | ||||||||||
EBITDA | 30.1M | 45.01M | 9.06M | -10.94M | -32.53M | |||||
EBITA | 28.72M | 43.64M | 7.84M | -11.86M | -33.39M | |||||
EBIT | 27.24M | 42.16M | 6.33M | -13.95M | -40.66M | |||||
EBITDAR | 32.8M | 47.71M | 11.66M | -8.34M | -29.88M | |||||
Total Revenues (As Reported) | 248M | 269M | 254M | 193M | 199M | |||||
Effective Tax Rate - (Ratio) | 26.28 | 21.74 | 44.47 | 60.42 | 17.54 | |||||
Current Domestic Taxes | 2.06M | 2.2M | 3.71M | 5.02M | 2.4M | |||||
Current Foreign Taxes | 68K | 267K | 185K | 91K | 58K | |||||
Total Current Taxes | 2.13M | 2.47M | 3.9M | 5.12M | 2.46M | |||||
Deferred Domestic Taxes | 6.23M | 6.72M | 1.13M | -1.27M | -6.48M | |||||
Deferred Foreign Taxes | -42K | 22K | 3K | -15K | -3K | |||||
Total Deferred Taxes | 6.19M | 6.74M | 1.13M | -1.28M | -6.48M | |||||
Normalized Net Income | 19.78M | 26.48M | 7.06M | -1.54M | -18.7M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 12.6M | 6.7M | 2.6M | 500K | 1.9M | |||||
Selling and Marketing Expenses | 12.6M | 6.7M | 2.6M | 500K | 1.9M | |||||
Research And Development Expense From Footnotes | 55.58M | 75.36M | 85.77M | 76.82M | 74.43M | |||||
Net Rental Expense, Total | 2.7M | 2.7M | 2.6M | 2.6M | 2.65M | |||||
Stock-Based Comp., R&D Exp. (Total) | 3.8M | 3.96M | 3.96M | 3.32M | 2.96M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 9.56M | 11.42M | 12.32M | 10.72M | 9.47M | |||||
Total Stock-Based Compensation | 13.36M | 15.37M | 16.28M | 14.04M | 12.43M |
- Stock Market
- Equities
- VNDA Stock
- Financials Vanda Pharmaceuticals Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















